Skip to main content

WAVE Life Sciences

Wave Life Sciences Ltd is a clinical-stage genetic medicine company developing stereopure RNA therapeutics utilizing its proprietary PRISM platform. The company advances oligonucleotide therapies targeting genetic disorders including Duchenne muscular dystrophy (WVE-N531), Huntington's disease (WVE-003), alpha-1 antitrypsin deficiency (WVE-006), and obesity. Principal revenue is driven through research milestone payments, strategic development partnerships, and capital raises prior to commercial authorization. Core end markets serve pediatric neurology clinics, rare disease institutes, pulmonology centers, and genetic prescription patients globally. Wave Life Sciences holds an innovative position in the biopharmaceutical sector for stereopure oligonucleotide RNA drug engineering. The company is incorporated in Singapore, headquartered in Cambridge, Massachusetts, and its ordinary shares trade on the Nasdaq Global Market.

7 of the funds FundTelligence covers report a position in WAVE Life Sciences.

Legal name
WAVE Life Sciences Ltd
Sector
Health Care
Country
Singapore
Funds holding it
7
Exposure themes
Genetic Medicine, Precision Medicine & Genomics, RNA Therapeutics

Funds holding WAVE Life Sciences

Loading...